242 related articles for article (PubMed ID: 26833741)
1. Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment.
Kuracha MR; Thomas P; Loggie BW; Govindarajan V
Cancer Med; 2016 Apr; 5(4):711-9. PubMed ID: 26833741
[TBL] [Abstract][Full Text] [Related]
2. Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment.
Lohani K; Shetty S; Sharma P; Govindarajan V; Thomas P; Loggie B
Ann Surg Oncol; 2014 May; 21(5):1441-7. PubMed ID: 24046117
[TBL] [Abstract][Full Text] [Related]
3. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
Choudry HA; Mavanur A; O'Malley ME; Zeh HJ; Guo Z; Bartlett DL
Ann Surg Oncol; 2012 May; 19(5):1402-9. PubMed ID: 22302271
[TBL] [Abstract][Full Text] [Related]
4. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei.
Ronnett BM; Seidman JD
Am J Surg Pathol; 2003 May; 27(5):650-7. PubMed ID: 12717249
[TBL] [Abstract][Full Text] [Related]
5. Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases.
Yan F; Lin Y; Zhou Q; Chang H; Li Y
Hum Pathol; 2020 Mar; 97():9-18. PubMed ID: 31926211
[TBL] [Abstract][Full Text] [Related]
6. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
7. Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei.
Akashi S; Kuwabara H; Yasuda E; Akutagawa H; Takeshita A; Kurisu Y; Egashira Y; Hirose Y; Yuki M; Tsuda Y; Hayashi M
Diagn Cytopathol; 2016 Jul; 44(7):628-31. PubMed ID: 27079739
[TBL] [Abstract][Full Text] [Related]
8. Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype.
Flatmark K; Reed W; Halvorsen T; Sørensen O; Wiig JN; Larsen SG; Fodstad Ø; Giercksky KE
BMC Cancer; 2007 Jun; 7():116. PubMed ID: 17603904
[TBL] [Abstract][Full Text] [Related]
9. In vivo model of pseudomyxoma peritonei for novel candidate drug discovery.
Chua TC; Akther J; Yao P; Morris DL
Anticancer Res; 2009 Oct; 29(10):4051-5. PubMed ID: 19846950
[TBL] [Abstract][Full Text] [Related]
10. [Establishment of patient derived xenograft model of high-grade mucinous carcinoma peritonei accompanied with signet ring cells and identification of biological characteristics].
Lin YL; Zhang J; Yang ZR; Li XB; Ji ZH; Xu HB; Yan FC; Zhou Q; Peng Z; Li Y
Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):923-931. PubMed ID: 31874550
[No Abstract] [Full Text] [Related]
11. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y
Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of NCC-PMP2-C1: a novel patient-derived cell line of pseudomyxoma peritonei with signet ring cells.
Noguchi R; Yoshimatsu Y; Sin Y; Ono T; Tsuchiya R; Yoshida H; Kiyono T; Yonemura Y; Kondo T
Hum Cell; 2024 Mar; 37(2):511-522. PubMed ID: 38143259
[TBL] [Abstract][Full Text] [Related]
13. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
14. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process.
Carr NJ; Cecil TD; Mohamed F; Sobin LH; Sugarbaker PH; González-Moreno S; Taflampas P; Chapman S; Moran BJ;
Am J Surg Pathol; 2016 Jan; 40(1):14-26. PubMed ID: 26492181
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.
Noguchi R; Yano H; Gohda Y; Suda R; Igari T; Ohta Y; Yamashita N; Yamaguchi K; Terakado Y; Ikenoue T; Furukawa Y
Cancer Med; 2015 Dec; 4(12):1809-16. PubMed ID: 26475379
[TBL] [Abstract][Full Text] [Related]
16. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
Bibi R; Pranesh N; Saunders MP; Wilson MS; O'dwyer ST; Stern PL; Renehan AG
Br J Cancer; 2006 Nov; 95(9):1258-64. PubMed ID: 17031402
[TBL] [Abstract][Full Text] [Related]
17. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
O'Connell JT; Tomlinson JS; Roberts AA; McGonigle KF; Barsky SH
Am J Pathol; 2002 Aug; 161(2):551-64. PubMed ID: 12163380
[TBL] [Abstract][Full Text] [Related]
18. Pathologic diagnosis, origin, and natural history of pseudomyxoma peritonei.
Buell-Gutbrod R; Gwin K
Am Soc Clin Oncol Educ Book; 2013; ():221-5. PubMed ID: 23714507
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei.
Shih IM; Yan H; Speyrer D; Shmookler BM; Sugarbaker PH; Ronnett BM
Am J Surg Pathol; 2001 Aug; 25(8):1095-9. PubMed ID: 11474297
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal Malignancies).
Vlaeminck-Guillem V; Bienvenu J; Isaac S; Grangier B; Golfier F; Passot G; Bakrin N; Rodriguez-Lafrasse C; Gilly FN; Glehen O
Ann Surg Oncol; 2013 Aug; 20(8):2655-62. PubMed ID: 23519518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
